Investors File Securities Fraud Class Action Against Aardvark Therapeutics

A securities fraud class action lawsuit has been filed against Aardvark Therapeutics, Inc. The suit alleges that the company provided misleading information to investors in violation of federal securities laws.

Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notified investors of the pending lawsuit. The action targets investors who purchased or acquired Aardvark common stock during a specific period, alleging that the company made false or misleading statements that impacted its stock price.

Investors who purchased Aardvark Therapeutics stock and wish to learn more about their rights or eligibility to serve as a lead plaintiff are urged to contact Hagens Berman. The deadline to file a lead plaintiff motion is October 13, 2026.

The lawsuit seeks to recover damages on behalf of the affected investors. Aardvark Therapeutics has not yet publicly responded to the allegations in the lawsuit.